IGF1R and cholangiocarcinoma: In vitro studies with Sorafenib treatment revealed contrasting results [10,11]: Huether et al. were able to demonstrate the inhibition of cell growth in CCA cell lines by showing that a combined treatment of Sorafenib with Doxorubicin or insulin-like growth factor-1 receptor (IGF-1R)-inhibition resulted in additive antiproliferative effects.